<p>Spike glycoprotein (S), one of the signature proteins of the SARS-CoV-2, initiates the membrane fusion and virus entry to the host cell. The S protein’s key role in virus viability makes it an attractive candidate for drug design studies. Besides the recent structural characterization of the S protein, information fundamental to drug design such as possible binding sites or molecular fragments with high affinity towards the protein is unknown. We explored the druggability of this protein, focusing on its S1 and S2 domains. We performed virtual screening studies on both closed and open forms of the protein, using both cryo-EM structures and geometries obtained from molecular dynamic simulations. We targeted 20 distinct ligand binding centres with a set of about 9,000 molecules. Our docking calculations followed by molecular mechanics-based refinement of ligand/protein complexes led us to detect eight binding sites that were so far undocumented. By further focusing on a subset of approximately 1,000 approved and marketed drugs, we aimed at suggesting a new direction for drug repurposing strategies that were not considered so far. Within this approved set, our best hits include a number of antibacterial and antiviral drugs (e.g., Streptomycin, Nelfinavir), which were not yet investigated clinically in treating COVID-19. We also identified some molecules (e.g., folic acid, Famotidine) that were already suggested to be effective towards SARS-CoV-2, yet without molecular explanation. Our results also indicate a great affinity of SARS-CoV-2’s S protein towards nucleoside analogues, either approved or experimental.</p>
<p>Spike glycoprotein (S), one of the signature proteins of the SARS-CoV-2, initiates the membrane fusion and virus entry to the host cell. The S protein’s key role in virus viability makes it an attractive candidate for drug design studies. Besides the recent structural characterization of the S protein, information fundamental to drug design such as possible binding sites or molecular fragments with high affinity towards the protein is unknown. We explored the druggability of this protein, focusing on its S1 and S2 domains. We performed virtual screening studies on both closed and open forms of the protein, using both cryo-EM structures and geometries obtained from molecular dynamic simulations. We targeted 20 distinct ligand binding centres with a set of about 9,000 molecules. Our docking calculations followed by molecular mechanics-based refinement of ligand/protein complexes led us to detect eight binding sites that were so far undocumented. By further focusing on a subset of approximately 1,000 approved and marketed drugs, we aimed at suggesting a new direction for drug repurposing strategies that were not considered so far. Within this approved set, our best hits include a number of antibacterial and antiviral drugs (e.g., Streptomycin, Nelfinavir), which were not yet investigated clinically in treating COVID-19. We also identified some molecules (e.g., folic acid, Famotidine) that were already suggested to be effective towards SARS-CoV-2, yet without molecular explanation. Our results also indicate a great affinity of SARS-CoV-2’s S protein towards nucleoside analogues, either approved or experimental.</p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.